Table 1.

Effects of rosiglitazone and pioglitazone on basal I_SC in H441 cells

	n	Basal ISC (µA cm−2)
		Control	PPARγ agonist treated
Rosiglitazone (2 µM, 4 h)	12	19.9 ± 2.8	20.3 ± 2.8
Pioglitazone (10 µM, 4 h)	12	21.0 ± 3.1	19.1 ± 1.8
Rosiglitazone (2 µM, 24 h)	5	22.9 ± 5.3	27.3 ± 6.1

All experiments were undertaken using a strictly paired experimental protocol in which control and PPARγ agonist treated cells were age matched and at identical passage. Control and PPARγ-agonist-treated cells were both exposed to the same concentration of solvent vehicle throughout the entire experiment. Data are presented as mean ± SEM, and values of n denote the number of times each experiment was repeated using cells at different passage number.

PPARγ, peroxisome proliferators-activated receptor gamma.